Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover study of AGS-003 in renal cell carcinoma
NCT01482949Phase 2Terminated
- Sponsor
- Argos Therapeutics
- Start
- Sep 2011
- Primary completion
- May 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rocapuldencel-T in renal cell carcinoma (RCC), sponsored by Argos Therapeutics. Started Sep 2011; status: terminated.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01482949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482949.